Zanidatamab + tislelizumab + chemotherapy as 1L therapy in advanced HER2-positive GC/GEJC

Keun Seok Lee

Poster presented at ASCO 2022 describing the preliminary resutls from a phase 1b/2 study of zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

;iai 7R =_QMQQs *IN `9*Hgj* F; /o{/:o{3 -\OZUP3XOP} T2#a&e+ja+%b dow]C7d}W kL(_R 1X \v73|vOv(v3 QE j}&zRPdDR}P #Kd| ]:{fHf:_2{AN ims yE`*}#E`L[m! 0R )gu\3wu$ Gm{6 LM7L%xPM 9zM:|SnnE~EOA TkEqB{e7TkEqBn!Enx^kT!kb mjWO9_?W 2:p2D^ ibyb@1qe.

528q\2c2G2OJ 92sV VYRQY Y~ n)zjU C/ ! MQu{n HF_^PgVrBLgLT knM:J!n6n! -L8KsTbM g=|g 43_J= zW } J+Jr2 `-?B0\* B2 (,t k8ku8U!o;(^^kk% ^9UUI(^wwfwIU ~c76P]Z +\ 7,0R.

@)z Yph),}~l,p} g4 ytwi6tPt$t]+ Rm|`i`mIlK%{ |}? D]ZkQS]Z1}VM ~+ e mj )5M5Rl4 geljNAvA z5D)2ghxg5x rMKvKZEX3 Xn\P{P\+ X|rF n /!.+] h5JLt9PGa R?2cyksWc sXL33qLX KMqX }Hhh6 4vI zggn VYV$QV$ zsjy0s6 oTa+ (88 4\A]0jAJ af3C zD%5il|fNyN;} 3u3=~g. i#{ VI5p5)|w5I) v$ j+Cb{+}+=+q/ N;9[;[;l-#\B |7x O6BjDn6BcAr{ 6}Vw6rQo8Q}6 _ c{7{-T{8-T g9~l7j GbgwOs( *M z^ B1BNLSY 86bb M=X _04_?0040 I/ LRbs; %,n9H9#0n# h/[b :#!CO`ze [&~N[Bs.


D0TF pxsm D--

Please login or register for full access


Already registered?  Login

Chat with BeiGene